摘要
本研究比较去甲氧柔红霉素(IDA)联合阿糖胞苷(Ara-C)(IA)方案与柔红霉素(DNR)联合阿糖胞苷(Ara-C)(DA)方案治疗初治急性髓系白血病M2a(AML-M2a,急性粒细胞白血病部分分化型)患者的疗效和预后,以寻求更佳的治疗方案。收集2009年5月至2013年5月在本院住院治疗的AML-M2a患者65例,并进行了回顾性分析。结果表明,1 IA组诱导完全缓解率和有效率虽略高于DA组,但差异无统计学意义(P>0.05)。2 IA组白细胞最低值[(0.58±0.40)×109/L]明显低于DA组[(0.99±0.67)×109/L],差异有统计学意义(P<0.05);IA组中性粒细胞最低值[(0.19±0.09)×109/L]显著低于DA组[(0.21±0.16)×109/L],差异有统计学意义(P<0.05);IA组粒缺持续时间(12.59±5.31)d较DA组(9.17±7.04)d明显延长,差异有统计学意义(P<0.05)。3 IA组中位生存期(36.67个月)高于DA组中位生存期(21.45个月),差异有统计学意义(P<0.05)。4初诊时乳酸脱氢酶(LDH)值和初次诱导化疗方案是影响患者预后的独立危险因素。结论:IA方案与DA方案比较,可延长中位生存期,且远期疗效较好,可作为初治AML-M2a的首选化疗方案。
This study was purposed to compare the therapeutic efficacy and prognosis of acute myeloid leukemia M2a （AML-M2a） patients treated by idarubicin （IDA） combined with cytarabine （Ara-C） （IA） and daunorubicin （DNR） combined cytarabine （Ara-C） （DA） reginens. The clinical data of 65 patients with AML-M2a in our hospital were collected from May 2009 to May 2013 and analyzed. The results indicated the complete remission in IA group was slightly higher than that in DA group, there was no statistically significant difference （ P 〉 0.05 ） ; leukocyte minimum value in IA group [ （ 0.58 ±0.40） × 109/L ] was obviously lower than that in DA group [ （ 0.99 ± 0.67 ）× 109//L 1 （ P 〈 0.05） ; neutrophil minimum value in IA group [ （0.19 ±0.09）× 109/L] was significantly lower than that in DA group [ （0.21 ± 0.16）× 109/L ] （P 〈 0.05 ） ; the neutropenia duration in IA group （12.59±5.31 ）d was much longer than that in DA group （9.17 ± 7.04） d （ P 〈 0.05 ）. The median survival time of patients in IA group was 36.67 months, which was obviously longer than that of patients in DA group （21.45 months） （P 〈 0.05 ）. The lactate dehydrogenase （LDH） value and chemotherapy regimens were the independently risk factor affecting the prognosis of AML-M2a patients. It is concluded that as compared with DA regimen, the IA regimen can prolong the median survival time and has better long-term therapeutic efficacy, thus it can be used as the first chemotherapy regimen for treatment of AML- M2a.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2014年第4期976-981,共6页
Journal of Experimental Hematology
